

# ISEH - '86 ABSTRACT FORM

Deadline for receipt of Abstract  
March 17, 1986

For Office Use Only

Perm. Abst. No. .... Temp. Abst. No. ....

Type abstract here — You must stay within border

PREFERENCE: ☒ Poster ☐ Platform

CHECK ONE: ☐ Clinical ☒ Non-clinical

## CHECK THREE KEY AREAS:

### BONE MARROW TRANSPLANTATION

- |   |   |
|---|---|
| <input type="checkbox"/> In malignancies        | <input type="checkbox"/> Immunosuppression      |
| <input type="checkbox"/> In leukemia            | <input type="checkbox"/> GVHD                   |
| <input type="checkbox"/> In aplastic anemia     | <input type="checkbox"/> Preparative regimens   |
| <input type="checkbox"/> Autologous transplants | <input type="checkbox"/> Stem cell purification |
| <input type="checkbox"/> Histocompatibility     | <input type="checkbox"/> Marrow purging         |
| <input type="checkbox"/> Gene therapy           | <input type="checkbox"/> Complications          |

### DIFFERENTIATION

- |   |   |
|---|---|
| <input type="checkbox"/> Stem cells               | Granulocytopoiesis:                                 |
| <input type="checkbox"/> Extracellular matrix     | <input type="checkbox"/> Neutrophils                |
| <input type="checkbox"/> Erythropoiesis           | <input type="checkbox"/> Eosinophils                |
| <input type="checkbox"/> Cell:Cell interactions   | <input type="checkbox"/> Basophils                  |
| <input type="checkbox"/> Differentiation antigens | <input type="checkbox"/> Megakaryocytes & platelets |
|   | <input type="checkbox"/> Gene action                |
|   | <input type="checkbox"/> Lymphopoiesis              |
|   | <input type="checkbox"/> Microenvironment/stroma    |
|   | <input type="checkbox"/> Monocytopoiesis            |

### HEMOPOIETIC REGULATORY FACTORS

- |  |  |
|--|--|
| <input checked="" type="checkbox"/> Biochemical characterization | <input type="checkbox"/> Production            |
| <input type="checkbox"/> Receptors                               | <input checked="" type="checkbox"/> Inhibitors |
| <input type="checkbox"/> Mechanism of action                     | <input type="checkbox"/> Poietins              |
|  | <input type="checkbox"/> Growth factors        |

### LYMPHOPOIESIS & LYMPHOCYTE FUNCTION

- |  |   |
|--|---|
| <input type="checkbox"/> Cytotoxic cells           | <input type="checkbox"/> Clonogenic progenitors           |
| <input type="checkbox"/> Immune deficiency disease | <input type="checkbox"/> Lymphopoietic regulatory factors |

### HEMATOLOGIC MALIGNANCIES

- |   |   |
|---|---|
| <input type="checkbox"/> Leukemia               | <input type="checkbox"/> Differentiation inducers             |
| <input type="checkbox"/> Lymphomas              | <input type="checkbox"/> Oncogenes                            |
| <input type="checkbox"/> Myelomas               | <input type="checkbox"/> Immunotherapy                        |
| <input type="checkbox"/> Etiology               | <input checked="" type="checkbox"/> Experimental chemotherapy |
| <input type="checkbox"/> Proliferation inducers |   |

### MOLECULAR BIOLOGY

- |  |
|--|
| <input type="checkbox"/> Genes and gene products |
| <input type="checkbox"/> Molecular probes        |
| <input type="checkbox"/> Monoclonal antibodies   |

PLURONIC F-68 PROTECTION OF RED CELL MEMBRANE INTEGRITY. McPherson, JC Jr\*, Ward, DF\*, Kirby, SG\*, McPherson, JC III\* (intro. by Felice, A). Medical College of Georgia, Augusta, and Dept Clin Invest, Eisenhower Army Med Ctr, Ft Gordon, GA.

Pluronic F-68 (F-68), a surfactant, has been used in i.v. fat emulsions and artificial blood emulsions as a co-emulsifying agent. In this study we have examined the effect of F-68 on the red blood cell (RBC) membrane in vitro. Because of its high molecular weight (8,350 g/M), aqueous solutions are hypotonic to RBC's. Solutions of 20, 10, 5, 2.5 and 1.25% wt/vol in distilled water were prepared (calculated mOsm: 24, 12, 6, 3, 1.5; measured mOsm: 600(?), 78, 17, 1, 0 by freezing point method). Five ml of each dilution of F-68 were mixed with 25 ul of whole rat blood (samples from 10 rats) and after 30 minutes, centrifuged, and the free hemoglobin measured in the supernatant at 540 nm (osmotic fragility test method, Brown, BA, Hematology, 4th ed, p 903, 1984). F-68 protected the cells from hypotonic hemolysis: 14, 20, 54, 73, 90% hemolysis, respectively. Protection of the RBC against mechanical trauma was evaluated by a modified mechanical fragility (MF) test by suspending the RBC's in 1% PBS (control) and in 1% F-68 in PBS. The MF in PBS was 50% hemolysis compared to 1.3% in F-68. Protection of the RBC membrane against thermal damage was evaluated by heating suspensions of rat RBC's in 1% PBS and in 10% F-68 in PBS (isotonic) for 20 minutes at 47° and 55°C. Osmotic fragility (OF) tests and MF tests were performed on these cooled suspensions. F-68 protected the cells against OF and MF (87% control vs 1.25% in F-68) at 47° but provided no protection at 55°C. F-68 probably exerts its effect by associating with the lipids and/or the proteins in the RBC membrane providing increased stability against stress on the membrane. F-68 may be useful in prolonging RBC life span in some clinical states.

### CORRESPONDING AUTHOR:

Name..... James C. McPherson, Jr.  
Address..... Dept Surgery, Medical College of Georgia,  
Augusta, GA 30912  
Signature of member sponsor..... *Felice*  
Presented by..... J. C. McPherson, Jr.

Airmail to: Dr. Michael P. McGarry  
ISEH-'86  
Roswell Park Memorial Institute  
666 Elm Street  
Buffalo, NY 14263 USA